http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#Head http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#provenance http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#pubinfo http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion http://purl.obolibrary.org/obo/DOID_9408 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9408 http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00009 http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association http://www.w3.org/2000/01/rdf-schema#label activase is a tissue plasminogen activator tpa indicated for the treatment of acute ischemic stroke ais 1 1 acute myocardial infarction ami to reduce mortality and incidence of heart failure 1 2 limitation of use in ami 1 2 acute massive pulmonary embolism pe for lysis 1 3 activase is indicated for the treatment of acute ischemic stroke exclude intracranial hemorrhage as the primary cause of stroke signs and symptoms prior to initiation of treatment see contraindications 4 1 activase is indicated for use in acute myocardial infarction ami for the reduction of mortality and reduction of the incidence of heart failure limitation of use activase is indicated for the lysis of acute massive pulmonary embolism defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments acute pulmonary emboli accompanied by unstable hemodynamics e g failure to maintain blood pressure without supportive measures http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00009 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#provenance http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#pubinfo http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig http://purl.org/nanopub/x/hasSignature GGqC+dUkQJsevZ3+T+JhWKjrtiuZIL6hh7wB/cxWj1dnFa01sWa3muqHyDB6IasMu5zjmUuE1FWL5vTFT6p5agmqiikOFi2Ip5qReoJ8YlsglwntIqw3lgahzhOG88VIdmQtUlFo2D0Xfdlhx8E9EsNX0Ix77/f2l3Qrxj7xMWo= http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://purl.org/dc/terms/created 2021-06-12T12:20:18.779+02:00 http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RANQqkW-R2MQW_Cei8VrhVFx0TtFloC7eEZCbb4izQcks https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs